Skip to main content

Table 2 Baseline characteristics of randomised groups

From: A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study

  Placebo then donepezil (n = 10) Donepezil then placebo (n = 8)
Gender 4 male, 6 female 1 male, 7 female
Handedness 10 right 3 left, 5 right
Age (years) 60.2 (7.3) 62.9 (6.0)
Disease duration (years) 3.3 (1.9)a 3.7 (1.5)
MMSE 23.9 (4.0) 22.6 (3.2)
Simple calculation 6.9 (1.4)b 7.3 (1.0)a
Number location 3.9 (2.8) 3.8 (2.9)
Letter cancellation 59.8 (21.5) 91.9 (19.7)
Dot counting 5.3 (2.6)a 5.1 (3.6)a
Digit span 13.4 (3.0)a 13.6 (4.4)a
  1. Data presented as mean (standard deviation) unless otherwise stated
  2. MMSE Mini-Mental State Examination
  3. aOne missing value
  4. bTwo missing values